Edding Genor Group Holdings Limited announced the successful completion of the first subject dosing on 5 August 2026 in its Phase Ib/II clinical trial of GB268, a PD-1/CTLA-4/VEGF trispecific antibody targeting locally advanced unresectable or metastatic breast cancer, including triple-negative breast cancer and HR+/HER2- subtypes.

The multi-arm study evaluates GB268 as monotherapy, in combination with chemotherapy, and alongside antibody-drug conjugates. Primary endpoints focus on safety and tolerability—specifically dose-limiting toxicity—and preliminary anti-tumor activity across treatment regimens.

The protocol spans first-line through later-line settings, positioning GB268 for broad clinical exploration. Edding Genor also plans to initiate additional combination-therapy trials in other advanced solid tumors. Phase I monotherapy data are scheduled for presentation at the European Society for Medical Oncology (ESMO) congress in the fourth quarter of 2026.